ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020
ObsEva SA (NASDAQ: OBSV) announced that CEO Ernest Loumaye will present an update on the company’s pipeline at the Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 9:45 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV) announced that CEO Ernest Loumaye will present an update on the company’s pipeline at the Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 9:45 a.m. ET. Investors can access a live presentation link via the Events Calendar on ObsEva’s website. ObsEva is focused on innovative therapies for women’s reproductive health, including treatments for endometriosis, uterine fibroids, and preterm labor. The company is also traded on the SIX Swiss Exchange under the ticker “OBSN”.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Wedbush PacGrow Virtual Healthcare Conference taking place August 11 - 12, 2020.
Mr. Loumaye’s presentation will take place on Wednesday August 12, 2020 at 9:45 a.m. Eastern Time (ET). A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.